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Abstract 
Background: Malignant pleural mesothelioma (MPM) is an aggressive neoplasm of the pleura, mainly related to 
asbestos exposure. As in other solid tumors, malignant cells exhibit high glucose uptake and glycolytic rates with 
increased lactic acid efflux into the interstitial space. Lactate transport into and out of cells, crucial to maintaining 
intracellular pH homeostasis and glycolysis, is carried out by monocarboxylate transporters (MCTs) and the chaperone 
basigin (CD147). We set out to examine the clinical significance of basigin, MCT1 and MCT4 in the context of MPM 
and to evaluate their expression in relation to the evolution of the disease.
Methods: We used immunohistochemistry to measure the expression of basigin, MCT1 and MCT4 in a cohort of 
135 individuals with MPM compared to a series of 15 non-MPM pleura specimens. Moreover, by Kaplan–Meier and 
Cox analyses we evaluated whether an expression over the average of these markers could be associated with the 
patients’ overall survival (OS).
Results: We detected positive staining of basigin, MCT1, and MCT4 in most MPM specimens. In particular, MCT4 was 
always positive in malignant tissues but undetectable in the 4 normal pleural specimens incorporated within the tis-
sue microarray. This was confirmed in the additional series of 15 normal pleural samples. Moreover, MCT4 expression 
was significantly associated with reduced OS.
Conclusion: In this study, the tissue expression of basigin did not prove to be exploitable as a diagnostic or prognos-
tic marker for MPM patients. The expression of MCT1 was not informative either, being tightly correlated with that of 
basigin. However, the expression of MCT4 showed promise as a diagnostic/therapeutic and prognostic biomarker.
Keywords: Malignant pleural mesothelioma (MPM), MCT1, MCT4, Basigin (CD147), Immunohistochemistry (IHC), 
Tissue microarray (TMA)
© The Author(s) 2020. This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, 
adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and 
the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material 
in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material 
is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the 
permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creat iveco 
mmons .org/licen ses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creat iveco mmons .org/publi cdoma in/
zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Background
It is well-known that cancer cells can obtain energy by 
increasing their rates of glycolysis despite oxygen being 
available (Warburg effect) [1]. This metabolic shift 
generates intracellular lactic acid that is actively expelled 
causing extracellular acidification. Low interstitial pH has 
been associated with increased levels of VEGF, IL8, and 
heparanase that could trigger cancer autocrine stimula-
tion and enhance tumor aggressiveness [2]. Indeed, the 
accumulation of lactate in a wider range of solid cancers 
has been correlated with poor clinical outcome [3]. The 
monocarboxylate transporters (MCTs) are important 
players in this phenomenon. They mediate the co-trans-
port of lactate with a proton, thus regulating intracellular 
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and interstitial pH to maintain high glycolytic rates. 
MCT1 and MCT4 (encoded by the SLC16A1 and 
SLC16A3 genes, respectively) are considered the most 
important transporters in this process. Their activities 
appear to differ somewhat, with MCT1 mainly involved 
in the influx of lactate, whereas MCT4 is more impor-
tant in the efflux of lactate [4]. A third player is basigin, 
a type I transmembrane glycoprotein (also known as 
CD147) and encoded by the BSG gene [5]. Basigin func-
tions as a chaperone protein, by interacting with MCTs 
and stabilizing their localization at the cell membrane. 
Deregulated expression of basigin, MCT1, and MCT4 
has been reported in carcinoma of pancreas [6], uterine 
cervix [7], kidney (papillary and clear renal cell) [8] and 
bladder urothelium [9], suggesting that these molecules 
could represent attractive targets for novel therapies. 
Malignant pleural mesothelioma (MPM) frequently con-
tains highly hypoxic regions that might contribute to its 
aggressive behavior through the activation of the tran-
scription factor HIF-1α [10]. However, MCT transport-
ers and basigin have not been thoroughly investigated 
in MPM. Thus, it is conceivable that the expression of 
basigin, MCT1 and MCT4 could be related to MPM car-
cinogenesis and aggressiveness. To test this hypothesis, 
we assessed whether the expression of these molecules 
(evaluated by immunohistochemical staining, IHC) was 
associated with the malignant state or patients’ progno-
sis. The IHC analysis was performed on a tissue micro-
array (TMA) composed of diagnostic tissues from 135 
individuals with MPM [11] and four samples of normal 
pleura. Fifteen additional samples from normal pleura 
were also employed for a further validation of the results. 
The prognostic analysis was carried out with univariate 
and multivariate statistical tests where the histological 
subtype of mesothelioma (epithelioid, sarcomatoid, or 
biphasic) [12] was included into the model. To date, his-
tological subtype remains the main prognostic parameter 
for MPM patients [13, 14], with the epithelioid subtype 
having a better outcome than the sarcomatoid or bipha-
sic MPM.
Materials and methods
Ethical considerations
This study was approved via the generic Royal Papworth 
Hospital Tissue Bank ethical approval granted by the 
Cambridge Research Ethics Committee (REC reference 
08/H0304/56+5). The TMA sections used in this study 
were obtained from a TMA produced for a previously 
approved study (REC reference 09/H0311/21) [11]. For 
inclusion in the TMA, patients diagnosed with malig-
nant mesothelioma between 2005 and 2010 had been 
previously identified from hospital records. Their histol-
ogy slides and FFPE (formalin-fixed-paraffin-embedded) 
biopsy tissue blocks were retrieved from the pathol-
ogy archive and clinical data relating to each case were 
extracted from hospital records.
MPM tissue microarray and immunohistochemistry
The MPM TMA slides employed in this study were 
derived from the MPM TMA blocks previously con-
structed and used in the study by Dalton et al. [11]. Tis-
sue cores of samples from 135 patients diagnosed with 
malignant mesothelioma were included in the study. 
Immunohistochemistry was performed as described in 
the study by Dalton et al. [11]. We employed the follow-
ing antibodies: basigin (dilution 1:250; AB49493 Abcam), 
MCT1 (dilution 1:400; AB3538P Merk Millipore), or 
MCT4 (dilution 1:200; 376101 (F-10), Santa Cruz).
Scoring and statistical analysis
Scoring was performed, using PathXL software, by two 
independent and experienced histopathologists. The 
slides were scored semi-quantitatively and an aver-
age of staining intensity at the nuclear, cytoplasmic 
and membrane level was obtained for each patient. The 
sum of these scores provided the patients’ total value 
of intensity for basigin, MCT1, and MCT4 expression. 
Among positive patients, the average was calculated and 
employed as a cut-off value to define “low expressing” or 
“high expressing” patients. The use of the average inten-
sity allowed a more conservative definition of the “high 
expressing patients” as compared to the median being 
more sensitive to high values in skewed distributions [15, 
16].
Statistical comparisons were performed using log-rank 
tests for censored data. Statistical analyses were per-
formed using R and GraphPad software. The Kaplan–
Meier method was used to analyse the overall survival 
(OS). Correlation between variables was determined 
using the Spearman Rank test. Survival was calculated 
from the last day of treatment. Univariate log-rank test 
was used to calculate the significance between the sur-
vival curves. The Cox proportional hazards regression 
model was performed to estimate the independence of 
factors which correlated in univariate analysis with sur-
vival. Hazard ratios (HRs) were presented with 95% con-
fidence intervals (95% CI). A P value of less than 0.05 was 
considered statistically significant.
Evaluation of basigin, MCT1, and MCT4 expression 
in normal pleura samples
The antibodies and protocols used for the staining of 
normal pleura samples were the same as those used 
for the TMA IHC. Fifteen normal pleura samples were 
stained together with some selected cases of MPM, pre-
viously studied in the TMA IHC, in order to compare 
Page 3 of 7Dell’Anno et al. J Transl Med          (2020) 18:341  
the intensity and the localization of staining. The cases 
included lung tissue with some surface visceral pleural 
mesothelial cells and strips of parietal pleura from pneu-
mothorax patients.
Results
In order to evaluate further the expression of basigin, 
MCT1, and MCT4 in MPM, an IHC evaluation was per-
formed on a TMA containing 135 samples. Expression 
scores were obtained from 89, 88 and 90 patients, respec-
tively. All markers analyzed exhibited cytoplasmic and/or 
plasma membrane staining, with a predominance of the 
latter, as expected for membrane pumps. These metabo-
lism-related proteins were strongly expressed in both epi-
thelioid and sarcomatoid MPM (Fig. 1). Interestingly, we 
observed a co-expression of MCT1, but not MCT4, with 
basigin (P < 0.0001; Additional file 1: Figure S1 and Addi-
tional file 2: Table S1).
The expression of each marker was classified as low or 
high and analyzed in relation to the OS by the Kaplan–
Meier method. High expression of MCT4 was signifi-
cantly associated with shortened OS (log-rank P = 0.019, 
HR = 1.70; 95% CI 1.09–2.70). Patients with low expres-
sion of total MCT4 survived longer than patients with 
high expression. At one, two or three years after diag-
nosis, the OS of patients with low MCT4 was 70%, 40% 
and 20% respectively, as compared to 40%, 20% and 0% 
for patients with high MCT4 (Fig. 2). When only patients 
with epithelioid MPM were analysed (n = 68), the asso-
ciation between the OS and MCT4 was less evident (log-
rank P = 0.053, HR = 1.69, 95% CI 0.99–2.88) likely due to 
reduced statistical power. The same trend was observed 
for the other histological subtypes (n = 22 overall) lack-
ing any statistical significance due to the low power of the 
analyses. The Kaplan–Meier analyses, stratified by histo-
logical subtype, are provided in supplementary materials 
(Additional file  3: Figure  S2). Similar results for MCT4 
were obtained also in a multivariate analysis which 
included age, gender, tumor histological subtype, previ-
ous cancer diagnosis, type of therapy (surgery, radio- or 
chemotherapy), and mesothelial marker staining (WT1 
and calretinin). In this analysis, low expression of cal-
retinin and lack of therapeutic intervention were associ-
ated with a statistically significant short OS (Table 1). The 
results of the univariate analyses for each of the consid-
ered factors are reported in Table  2 and supplementary 
materials (Additional file 4: Figure S3). Overall, we could 
not find any statistically significant association between 
MPM patients’ OS and basigin or MCT1 levels (Fig. 2).  
In order to extend these observations, we queried the 
TCGA online resource (https ://porta l.gdc.cance r.gov/). 
In this database, transcriptomic information is avail-
able for 87 MPM samples. We extracted the expression 
levels of SLC16A3 (MCT4) and applied the Kaplan–
Meyer method for analyzing the OS. This analysis 
showed that a low mRNA expression of SLC16A3 is asso-
ciated with longer OS, consistent with our findings at the 
protein level. The median survival for patients with a high 
SLC16A3 expression was 400 days, but this value doubled 
in those patients with low SLC16A3 expression (Addi-
tional file 5: Figure S4; log-rank P = 0.004, HR = 2.47, 95% 
CI 1.34–4.53).
We next examined the expression of MCT4 in normal 
pleura. Sections of non-neoplastic pleura were obtained 
from specimens of fifteen individuals who had under-
gone bullectomy and pleurectomy for recurrent pneu-
mothorax, and who had previously given research tissue 
bank consent. These sections were stained together with 
selected cases of MPM in order to compare the intensity 
and localization of the signals. Interestingly, all samples 
of non-neoplastic mesothelial tissue were negative for 
MCT4 (Fig. 3 and Additional file 6: Figure S5), but posi-
tive for basigin and MCT1 (Additional file 7: Figure S6).
Discussion
In the present work, 135 core biopsy samples of MPM 
were examined by IHC for the expression of basigin, 
MCT1 and MCT4. Interestingly, we observed positive 
and cell compartment-specific staining for the three 
markers and a statistically significant co-expression of 
MCT1 and basigin in MPM tissues. This latter result is 
in agreement with previous studies reporting a positive 
association between MCT1, but not MCT4, and basigin 
expression in breast cancer and adrenocortical carcino-
mas [17, 18]. However, basigin or MCT1 levels were not 
found to be associated with the considered clinical vari-
ables. On the other hand, a high expression of MTC4 was 
found to be significantly associated with a short OS of 
MPM patients and a similar trend (at mRNA level) was 
also confirmed by the data available within the TCGA 
data portal. In addition, a lack of expression of MCT4 
was noticed for the 4 samples of healthy pleura incor-
porated within the TMA, suggesting a sharp difference 
between benign and malignant tissues. Thus, we verified 
this finding by extending the IHC analysis on 15 normal 
pleura tissues. It is noteworthy that non-malignant tis-
sues were negative for the expression of MCT4. This is in 
agreement with a previous observation reporting that the 
IHC expression of MCT4 was poor or lacking in a series 
of 20 samples of reactive mesothelial hyperplasia and 
markedly increased in a series of 35 human MPM [19]. 
Taken together these data strongly suggest that MCT4 
is a potential prognostic bio-marker for human MPM. 
However, we are aware that, in the view of an applica-
tion in a defined clinical context, the determination of the 
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sensitivity and predictive value must be addressed in fur-
ther studies [13, 20].
Increased expression of MCT4 by cancer cells enhances 
the interstitial concentrations of lactic acid and is, at least 
in part, responsible for the acidic tumour microenviron-
ment. Acidosis promotes extracellular matrix degradation 
and angiogenesis, inhibits the immune response and it is 
toxic for non-transformed cells [21]. Acidosis can also 
favour cell motility and invasion and could enhance the 
resistance to glucose-deprivation-induced apoptosis that 
could be reverted by buffering the interstitial pH towards 
physiological values [22]. The increased expression of 
Fig. 1 Immunohistochemistry demonstrating staining patterns for glycolytic markers, basigin, MCT1 and MCT4, in malignant pleural mesothelioma 
(MPM) cases. Representative images of epithelioid and sarcomatoid subtypes of mesothelioma showing membranous and cytoplasmic staining—
basigin (top), MCT1 (middle), and MCT4 (bottom) staining
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MCT4 in MPM tissues is in agreement with previous 
observations for other solid cancers. Elevated MCT4 lev-
els have been suggested as biomarker of poor prognosis 
Fig. 2 Kaplan–Meier analysis of the association of a basigin (low expression, n = 49; high expression, n = 40), b MCT1 (low expression, n = 51; high 
expression, n = 37), and c MCT4 (low expression, n = 56; high expression, n = 34) expression with overall survival (OS) among 88–90 patients. Blue 
line, patients showing high (H) marker expression; red line, patients showing low (L) marker expression
Table 1 Worse prognostic factors affecting OS 
by multivariate analyses
Statistical significance is indicated by asterisk (*), where * = P < 0.05, 
** = P < 0.01, *** = P < 0.001
Variables Unfavorable factor HR (95% CI) P
MCT4 High expression 1.67 (0.99–2.81) 0.054
Calretinin Low expression 0.25 (0.098–0.65) 0.004**
Therapeutic 
interven-
tion
Chemo/radio therapy or 
surgery
0.40 (0.17–0.92) 0.030*
Table 2 Univariate analysis of  clinicopathologic variables 
(calretinin expression, WT1 expression, histological 
subtype, therapy intervention, gender and  previous 
cancer diagnosis) for  overall survival in  MPM  patients, 
expressed as 95% confidence interval (95% Cl) and P-value 
(log-rank test)
Statistical significance is indicated by asterisk (*), where * = P < 0.05, 
** = P < 0.01, *** = P < 0.001
Variables HR (95% CI) P
Calretinin 0.24 (0.14–0.42)  < 0.0001***
WT1 0.52 (0.27–1.03) 0.06
Histotype 2.28 (1.51–3.44)  < 0.0001***
Therapeutic intervention 0.47 (0.27–0.82) 0.006**
Gender 0.73 (0.46–1.17) 0.19
Previous cancer 0.88 (0.50–1.54) 0.65
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in breast, bladder, pancreatic, hepatocellular, gastric, oral 
squamous cell and clear cell renal carcinoma, melanoma, 
soft tissue sarcomas, osteosarcoma, and lung adenocar-
cinoma (an extensive literature reference can be found 
in the Additional file 8) . MPM can now be added to this 
list. Furthermore, the association between high expres-
sion of MCT4 and decreased survival has also been 
documented for colorectal cancer with peritoneal car-
cinomatosis. High MCT4 expression has been shown to 
correlate with enhanced metastatic processes, especially 
in oesophageal adenocarcinoma [23] and in colorectal 
carcinoma [24, 25], and with invasion in gastric cancer 
[26].
Conclusions
In summary, we propose that MCT4 tissue expression 
could serve as a novel prognostic biomarker for patients 
with MPM and, given its biological role in cancer pro-
gression, a target for novel inhibitors in the fight of 
cancer [27]. Furthermore, it is conceivable that the inhi-
bition of MCT4 and the consequent reduced interstitial 
acidosis could enhance the response to immune check-
point inhibitors [21]. Finally, the collection of a broader 
number of healthy and malignant specimens could help 
to confirm whether MCT4 could also be exploited as a 
diagnostic biomarker.
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Additional file 1: Figure S1. Scatter plot representing the correlation 
between MCT1 and basigin IHC staining. 
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Statistical significance is indicated by asterisks (*), where * = P < 0.05; ** = 
P < 0.01; *** = P < 0.001, and **** = P < 0.0001. 
Additional file 3: Figure S2. Kaplan-Meier analysis of the association of 
basigin, MCT1, and MCT4 expression with overall survival (OS) among 
87–90 patients, stratified by histological subtype (“E” epithelioid or “O” 
other, including sarcomatoid and biphasic). Blue line: patients showing 
high marker expression; red line: patients showing low marker expression. 
Additional file 4: Figure S3. Association of OS with calretinin expression 
(0, red line = no relevance; 1, blue line = present), WT1 expression (0, 
red line = no relevance; 1, blue line = present), histological subtype (1, 
red line = epithelioid; 2, blue line = sarcomatoid, spindle and biphasic), 
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cancer diagnosis (0, red line = no; 1, blue line = yes). 
Additional file 5: Figure S4. Kaplan-Meier analysis of the association of 
SLC16A3 (encoding for MCT4) expression with OS for patients recorded 
in the Mesothelioma TCGA database (“TCGA-MESO”). Blue line, patients 
showing high (H) marker expression; red line, patients showing low (L) 
marker expression. 
Additional file 6: Figure S5. MCT4 staining in normal pleura samples. 
Seven representative pictures of fifteen normal pleura samples (acquired 
at 200X) showing that the staining with the MCT4 antibody in normal 
mesothelial cells provides largely negative results. 
Additional file 7: Figure S6. Basigin and MCT1 staining in normal 
pleura samples. Representative pictures of normal pleura samples 
showing that the staining with (A) basigin (acquired at 200X) or (B) MCT1 
antibody (acquired at 200X) in normal mesothelial cells provides largely 
positive results. 
Additional file 8: Additional literature references. Extensive literature 
references reporting MCT4 as putative biomarker in human cancers.
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